AbbVie Inc.

ABBV

US00287Y1091

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).

Sector

Pharmaceuticals

Calendar

25/07/2024 - Q2 2024 Earnings Release (Projected)

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for AbbVie Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

171.2 USD

Average target price

183.2 USD

Spread / Average Target

+7.06%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ABBVIE INC.	+9.24%	302B
ELI LILLY AND COMPANY	+54.64%	811B
NOVO NORDISK A/S	+43.62%	640B
JOHNSON & JOHNSON	-6.58%	353B
MERCK & CO., INC.	+18.37%	333B
ASTRAZENECA PLC	+16.72%	246B
ROCHE HOLDING AG	+2.49%	225B
NOVARTIS AG	+12.64%	218B
AMGEN INC.	+9.13%	168B
PFIZER, INC.	-5.47%	155B

Other Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 16:20:25 27/06/2024 BST			5-day change	1st Jan Change
169.4 ^USD	-1.01%		-1.65%	+9.24%

04:27pm	AbbVie: acquisition of Celsius for $250 million	CF
03:59pm	AbbVie Buys Celsius Therapeutics for $250 Million	DJ

AbbVie: acquisition of Celsius for $250 million	03:27pm	CF
AbbVie Buys Celsius Therapeutics for $250 Million	02:59pm	DJ
AbbVie Buys Celsius Therapeutics for $250 million	02:53pm	MT
AbbVie Buys Celsius Therapeutics for $250 million	02:34pm	MT
AbbVie Acquires Celsius Therapeutics in $250 Million Cash Deal	02:31pm	MT
Nxera Pharma Co Achieves Key R&D Milestone in Collaboration with AbbVie; Secures $10 Million Payment	12:59pm	MT
Nxera Pharma Co., Ltd. Receives USD 10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone	12:05am	CI
U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma	12:03am	CI
AbbVie Gets New FDA Accelerated Approval for Epkinly	06-26	DJ
FDA Again Rejects AbbVie Parkinson's Drug/Pump Combo -- Update	06-25	DJ
AbbVie Issues Regulatory Update on New Drug Application for ABBV-951 to Treat Parkinson's Disease	06-25	MT
FDA Again Rejects AbbVie Parkinson's Drug/Pump Combo	06-25	DJ
US FDA declines to approve AbbVie's Parkinson's disease therapy	06-25	RE
AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)	06-25	CI
AbbVie Keeps Quarterly Dividend at $1.55 per Share, Payable Aug. 15 to Shareholders of Record July 15	06-21	MT
AbbVie Inc. Declares Quarterly Cash Dividend, Payable on August 15, 2024	06-21	CI
AbbVie Says Skyrizi Gets FDA Approval For Ulcerative Colitis	06-20	MT
US FDA proposes to remove switching study requirement for biosimilars	06-20	RE
AbbVie Inc. Announces Board of Directors Changes	06-20	CI
AbbVie: FDA approval in ulcerative colitis	06-19	CF
U.S. FDA Approves Skyrizi® (Risankizumab-Rzaa) for Ulcerative Colitis, Expanding Abbvie's Portfolio Across Inflammatory Bowel Disease	06-18	CI
AbbVie's Skyrizi Gets FDA Approval to Treat Certain Instances of Ulcerative Colitis	06-18	DJ
Piper Sandler Adjusts Price Target on AbbVie to $190 From $185	06-18	MT
Future prospects for AI	06-18
AbbVie Says Investors Should Sit Out Tutanota Mini-Tender Offer	06-14	MT